drugset / Trial / NCT06897046
Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This project intends to study the efficacy and safety of Iparomlimab and Tuvonralimab with or without chemotherapyin the perioperative treatment of NSCLC
Timeline
- Start
- 2025-07-30
- Primary completion
- 2027-02-25
- Completion
- 2027-05-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Paclitaxel | Small molecule | — | — |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | — |
| Subject | QL1706 | Monoclonal antibody | 5 mg/kg | — |